FLC
RLMD icon

Fifth Lane Capital’s Relmada Therapeutics RLMD Stock Holding History

Fifth Lane Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,000
Closed -$313K – 39
2026
Q1 		$313K Buy
+45,000
New +$213K 0.38% 40

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fifth Lane Capital's RLMD Position: Q2 2026 in Review

Fifth Lane Capital sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 45,000 shares — an estimated $313K sold.

Fifth Lane Capital first reported a position in RLMD in Q1 2026 and held it in 1 quarter. The position peaked at $313K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Fifth Lane Capital reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fifth Lane Capital sold 45,000 Relmada Therapeutics shares in Q2 2026, an estimated $313K.
  • Fifth Lane Capital first reported a position in Relmada Therapeutics in Q1 2026 and held it in 1 quarter.
  • Fifth Lane Capital's Relmada Therapeutics position peaked at $313K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Fifth Lane Capital's 13F filing for Q2 2026, filed 6 Aug 2026.